Pfizer signs $5.3 billion COVID-19 oral antiviral drug deal with US government
Pfizer Inc has signed a $5.29 billion deal with the US government to deliver 10 million courses of its COVID-19 oral antiviral drug starting this year, the drugmaker said on Thursday.
The oral drug could be a promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prevent COVID-19 hospitalizations and deaths.
For more coronavirus news, visit our dedicated page.
Pfizer on Tuesday filed for US authorization of the drug, paxlovid, and said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.
“This promising treatment could help accelerate our path out of this pandemic by offering another life-saving tool for people who get sick with COVID-19,” said Xavier Becerra, secretary of the United States Department of Health and Human Services.
For the latest headlines, follow our Google News channel online or via the app.
The company earlier this month said the drug cut by 89 percent the chance of hospitalization or death for adults at risk of severe disease.
The trial’s results suggest that Pfizer’s drug surpasses Merck & Co Inc’s pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for COVID-19 patients at high risk of serious illness.
The US government has also signed a contract worth $2.2 billion for courses of the Merck drug.
Pfizer to allow generic versions of its COVID-19 pill paxlovid in 95 countries
AstraZeneca antibody drug 83 pct effective in preventing COVID-19
Merck’s COVID-19 pill partner in India sees a short-lived boom
Pfizer shot generates most COVID-fighting antibodies: Comparative studyPfizer Inc. and BioNTech SE’s COVID-19 shot yielded the strongest immune response among four vaccines tested in a study, which found people getting ... Coronavirus
Explainer: How does Merck’s COVID-19 pill compare to Pfizer’s?Pfizer Inc and Merck & Co Inc have developed experimental antiviral pills that have shown promising efficacy in trials of adults with COVID-19 who are ... Coronavirus
Pfizer says its antiviral pill cuts risk of severe COVID-19 by 89 percentA trial of Pfizer Inc’s experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89 percent the chances of ... Coronavirus
Benefits of Pfizer child COVID-19 vaccine shot likely outweigh risks: US FDAThe staff of the Food and Drug Administration said the benefits of Pfizer Inc. and BioNTech SE’s COVID-19 vaccine for young children likely outweigh ... Coronavirus